Predictive role of the overexpression for CXCR4, C-Met,and VEGF-C among breast cancer patients: A meta-analysis |
| |
| Institution: | 1. Laboratory of Molecular Genetics of Aging & Tumor, Medical Faculty, Kunming University of Science and Technology, Chenggong Campus, 727 South Jingming Road, Kunming, Yunnan 650500, China;2. First People''s Hospital of Yunnan Province, 157 Jinbi Road, Kunming, Yunnan 650032, China;1. Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California, 1 Shields Ave., Davis, CA, 95616, USA;2. Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical Sciences, Hiroshima University, Minami-ku, Kasumi 1-2-3, Hiroshima, 7348551, Japan;3. Department of Ophthalmology & Vision Science, School of Medicine, UC Davis Medical Center, 2315 Stockton Blvd, Sacramento, CA, 95817, USA;1. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;2. Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany;3. Department of Urology, Clinical Center Itzehoe, Itzehoe, Germany;4. Department of Urology, German Armed Forces Hospital, Hamburg, Germany;5. Department of Urology, Regio Clinic Wedel, Wedel, Germany;6. Institute of Pathology, University of Basel, Basel, Switzerland;1. Department of Respiratory Disease, The 117th hospital of PLA, Zhejiang, P.R. China;2. Department of Oncology, The 117th hospital of PLA, Zhejiang, P.R. China;1. Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China;2. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu 610041, China;3. Department of Information Engineering, Chongqing Vocational Institute of Safety Technology, Chongqing, 404020, China;1. Department of Respiratory Disease, The 117th Hospital of PLA, Hangzhou, Zhejiang, 310013, China;2. Military Clinical College of Hangzhou, Anhui Medical University, Hefei, Anhui, 230032, China |
| |
| Abstract: | BackgroundThe overexpression of CXCR4, C-Met and VEGF-C present widely in breast tumors, they may be markers of resistance to treatment. However, the studies are still controversial. Thus, this meta-analysis aims to research the relationship between the overexpression of CXCR4, C-Met, VEGF-C and clinical prognosis among breast cancer patients.MethodsPubMed and EMBASE databases were searched for eligible literature. The outcomes of interest were progression-free survival (PFS), relapse-free survival (RFS) and overall survival (OS). All tests of statistical significance were two sided.ResultsA total of 7830 patients from 28 eligible studies were assessed. The overexpression of the CXCR4 and C-Met both implied significantly worse PFS compared with normal expression HR = 2.56, 95% CI = 1.34–4.91, P = 0.005; and HR = 1.63 95% CI = 1.20–2.22, P = 0.002]. Meanwhile, if patients had high expression of CXCR4, they would have worse OS HR = 2.56 95% CI = 1.52–4.31, P = 0.000]. However, the overexpression of C-Met did not relate to OS for breast cancer patients HR = 1.16, 95% CI = 0.69–1.95, P = 0.570]. Meanwhile, no statistically significant different was observed with respect to PFS and OS between VEGF-C overexpression and normal expression HR = 0.99, 95% CI = 0.64–1.52, P = 0.968; and HR = 0.76, 95% CI = 0.43–1.33, P = 0.333].ConclusionsOur meta-analysis showed that CXCR4 and C-Met were efficient prognostic factors for breast cancer. Nevertheless, highly expressing VEGF-C was not related to progression-free survival and overall survival. Due to the small samples and insufficient date, further studies should be conducted to clarify the association between the overexpression of CXCR4 or C-Met or VEGF-C and the prognosis about breast cancer patients. |
| |
| Keywords: | CXCR4 C-Met VEGF-C Overexpression Breast cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
